Compare · HHLA vs NTRA
HHLA vs NTRA
Side-by-side comparison of HH&L Acquisition Co. (HHLA) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HHLA and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $56.90B, about 113.6x HHLA ($500.9M).
- NTRA has hit the wire 11 times in the past 4 weeks while HHLA has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 0 for HHLA).
- Company
- HH&L Acquisition Co.
- Natera Inc.
- Price
- -
- -
- Market cap
- $500.9M
- $56.90B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
HH&L Acquisition Co.
HH&L Acquisition Co. is a blank check company. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest HHLA
- SEC Form 25-NSE filed by HH&L Acquisition Co.
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G filed by HH&L Acquisition Co.
- SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)
- SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)
- HH&L Acquisition Co. Shares Halted Under Code News Pending
- HH&L Acquisition Co Decides That It Will Redeem All Of Its Outstanding Ordinary Shares That Were Included In Units Issued In Its IPO; Per-Share Redemption Price For Public Shares Will Be About $10.79, Before Payment Of Taxes And Dissolution Expenses
Latest NTRA
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $7,008,972 worth of shares (18,064 units at $388.01) as part of a pre-agreed trading plan (SEC Form 4)